Home > Insider Trading > Filing (0001239241-15-000004)

Filing Details

Accession Number:: 0001239241-15-000004
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-07-29 11:38:03
Reporting Period:: 2015-07-27

Filing Date:: 2015-07-29
Accepted Time:: 2015-07-29 11:38:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1594864	Juno Therapeutics Inc.	JUNO	Biological Products, (No Disgnostic Substances) (2836)	463656275

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1239241	B Anthony Evnin	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-07-27	80,740	$48.26	146,614	No	4	S	Indirect	By Funds
Common Stock	Disposition	2015-07-27	146,614	$47.82	0	No	4	S	Indirect	By Funds

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Funds
No	4	S	Indirect	By Funds

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	75,000	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Venrock Healthcare Capital Partners, L.P. ("VHCP") and VHCP Co-Investment Holdings, LLC ("VHCP Co-Invest") on May 18, 2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.07 to $49.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) - (6) to this Form 4.
On July 29, 2015, VHCP distributed an aggregate of 493,147 shares of the common stock of the Issuer to its respective partners pro rata based on their respective interests in VHCP (the "VHCP Distribution"). In connection with the VHCP Distribution, VHCP Management, LLC ("VHCP Management"), the general partner of VHCP, recevied an aggregate of 137,148 shares of the Issuer. Dr. Evnin did not receive any shares of the Issuer in connection wtih the VHCP Distribution, and with respect to Dr. Evnin, the VHCP Distribution did not represent a change in beneficial ownership.
Consists of 0 shares held by VHCP and 58,171, shares held by VHCP Co-Invest and 88,443 shares held by VHCP Management. VHCP Management is the general partner of VHCP and the manager of VHCP Co-Invest and may be deemed to beneficially own these shares. The reporting person is a member of VHCP Management and may be deemed to beneficially own these shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his indirect pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.50 to $48.06, inclusive.
Consists of 0 shares held by VHCP, 0 shares held by VHCP Co-Invest and 0 held by VHCP Management. VHCP Management, is the general partner of VHCP and the manager of VHCP Co-Invest and may be deemed to beneficially own these shares. The reporting person is a member of VHCP Management and may be deemed to beneficially own these shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his indirect pecuniary interest therein.